Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Subscribe To Our Newsletter & Stay Updated
